Stock NABRIVA THERAPEUTICS PLC - ADR
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. Nabriva Therapeutics PLC - ADR Nasdaq

Equities

US62957M1045

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Northland Capital Adjusts Nabriva Therapeutics' Price Target to $2 from $4, Keeps Outperform Rating
MT
NABRIVA THERAPEUTICS : Jefferies Starts Nabriva Therapeutics at Hold with $1.35 Price Target
MT
NABRIVA THERAPEUTICS : Northland Securities Adjusts Nabriva Therapeutics' Price Target to $6 from $9, Keeps Outperform Rating
MT
Nabriva Therapeutics plc Announces the Publication of A Study Documenting the High Rates of Macrolide-Resistant Streptococcus Pneumoniae Throughout the United States
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBRVF Stock
  4. Stock
  5. News Nabriva Therapeutics PLC - ADR
  6. Analyst Reco.